GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Rating of "Moderate Buy" from Analysts

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $72.33.

Several analysts have weighed in on the company. The Goldman Sachs Group upped their target price on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 10,559 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the transaction, the chief executive officer now owns 14,865 shares in the company, valued at approximately $1,437,594.15. The trade was a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Feeley sold 402 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10. Following the sale, the chief financial officer now directly owns 5,044 shares of the company's stock, valued at $454,212.20. The trade was a 7.38 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is currently owned by corporate insiders.

Remove Ads

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in WGS. MCF Advisors LLC lifted its stake in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares during the last quarter. Sterling Capital Management LLC lifted its stake in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx during the 4th quarter worth $28,000. Lazard Asset Management LLC purchased a new position in GeneDx in the 4th quarter worth about $35,000. Finally, Comerica Bank acquired a new stake in shares of GeneDx during the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Performance

Shares of GeneDx stock traded up $4.01 during trading hours on Wednesday, hitting $96.63. 856,334 shares of the company were exchanged, compared to its average volume of 674,054. GeneDx has a 1 year low of $8.63 and a 1 year high of $115.60. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The business has a 50-day moving average of $90.43 and a 200-day moving average of $78.37. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -49.30 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. As a group, analysts expect that GeneDx will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.